Find a Trial

Cardiovascular Clinical Trials

6 active studies and 13 selected completed trials. Search, filter by therapy area, and request a free pre-screen.

Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.

Active trials

6 active studies

Showing all 6 trials

Sort

Phase 2Heart FailureActive — enrolling

Pfizer BRANCH-HF (C4921003) — PF-07328948 in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Study purpose: To evaluate PF-07328948, an oral BCKD kinase inhibitor, and the role of branched-chain amino acid catabolism in cardiac function in adults with heart failure with preserved ejection fraction (HFpEF).
Who may qualify: Adults with heart failure and preserved ejection fraction (LVEF ≥ 50%) on stable medical therapy.
Commitment: Scheduled clinic visits with metabolic, biomarker, and cardiac assessments; full schedule confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Pfizer · ClinicalTrials.gov ID: NCT06991257

Read more Apply for screening

Phase 3HypertensionActive — enrolling

ZENITH — Zilebesiran in Uncontrolled Hypertension

Hypertension with Cardiovascular Risk

Study purpose: To evaluate whether zilebesiran, a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen, improves blood pressure control and cardiovascular outcomes in adults with uncontrolled hypertension and elevated cardiovascular risk.
Who may qualify: Adults 18+ with high blood pressure that is not adequately controlled and who have established cardiovascular disease or are at high cardiovascular risk.
Commitment: Subcutaneous study drug dosing with scheduled clinic visits; visit cadence confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Alnylam Pharmaceuticals · ClinicalTrials.gov ID: NCT07181109

Read more Apply for screening

Phase 3Heart FailureActive — enrolling

ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure

Iron-Deficiency Chronic Heart Failure

Study purpose: To evaluate whether intravenous ferric derisomaltose improves outcomes versus no intravenous iron in adults with symptomatic chronic heart failure and iron deficiency.
Who may qualify: Adults with chronic heart failure and lab-confirmed iron deficiency.
Commitment: Infusion visits and follow-up assessments over the study period.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Pharmacosmos · ClinicalTrials.gov ID: NCT06929806

Read more Apply for screening

PivotalVascularActive — enrolling

GREAT — Golazo® Peripheral Atherectomy System

Peripheral Artery Disease

Study purpose: To evaluate the safety and effectiveness of the Golazo® Peripheral Atherectomy System in patients with peripheral artery disease.
Who may qualify: Adults 18+ with symptomatic peripheral artery disease (Rutherford Class 2–4) and a suitable target lesion on imaging.
Commitment: Procedure with structured post-procedure follow-up; details reviewed at screening.
Location: Advanced Cardiovascular of Miami (affiliated ASC) · Miami, FL

Sponsor: Avantec Vascular · ClinicalTrials.gov ID: NCT06321575

Read more Apply for screening

Phase 1/2Heart FailureActive — enrolling

VASA — Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Ejection Fraction (HFpEF)

Study purpose: To evaluate the safety, tolerability, and biomarker profile of VS-041 in adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
Who may qualify: Adults with heart failure and preserved ejection fraction (LVEF ≥ 50%) on stable medical therapy.
Commitment: Multiple in-clinic visits with safety and biomarker assessments; full schedule confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Vasa Therapeutics, Inc. · ClinicalTrials.gov ID: Ask our research team

Read more Apply for screening

RegistryHeart FailureActive — start-up

OPEN HF Registry — Impulse Dynamics

Heart failure — cardiac contractility modulation (CCM)

Study purpose: A heart-failure registry of cardiac contractility modulation (CCM).
Who may qualify: Adults with heart failure. Full criteria confirmed at screening.
Commitment: Visit schedule confirmed at start-up and screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Impulse Dynamics · ClinicalTrials.gov ID: Ask our research team

Read more Apply for screening

All active trials

Every study currently active at Amavita Research, in one list. Use the search and filters above to narrow by condition or phase.

Pfizer BRANCH-HF (C4921003) — PF-07328948 in HFpEF
Phase 2 · Heart Failure with Preserved Ejection Fraction (HFpEF) · Active — enrolling
Trial details →
ZENITH — Zilebesiran in Uncontrolled Hypertension
Phase 3 · Hypertension with Cardiovascular Risk · Active — enrolling
Trial details →
ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure
Phase 3 · Iron-Deficiency Chronic Heart Failure · Active — enrolling
Trial details →
GREAT — Golazo® Peripheral Atherectomy System
Pivotal · Peripheral Artery Disease · Active — enrolling
Trial details →
VASA — Heart Failure with Preserved Ejection Fraction
Phase 1/2 · Heart Failure with Preserved Ejection Fraction (HFpEF) · Active — enrolling
Trial details →
OPEN HF Registry — Impulse Dynamics
Registry · Heart failure — cardiac contractility modulation (CCM) · Active — start-up
Trial details →

In start-up

AnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF
Phase 2B · Heart Failure with Reduced Ejection Fraction (HFrEF) · In start-up

Recently Completed

Studies in close-out within the last 12 months. Full study summaries below.

Phase 3Heart FailureTerminated Sep 2026 (NCT05636176).

HERMES — Ziltivekimab in Heart Failure

Heart failure with mid-range or preserved ejection fraction and systemic inflammation

Sponsor: Novo Nordisk · EX6018-4915 · NCT05636176

A Phase 3 randomized, placebo-controlled trial of ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation (protocol EX6018-4915). ClinicalTrials.gov lists the study as terminated (completion 3 Sep 2026). Amavita Research is not screening, and the study is not active.

View study summary

Phase 3ACSRecently completed.

LIBREXIA-ACS (Janssen — Milvexian)

Phase 3 — Acute Coronary Syndrome

Sponsor: Janssen · Janssen 70033093ACS3003 · NCT05754957

Pivotal Phase 3 LIBREXIA-ACS study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event. Recently completed.

View study summary

Phase 2Heart FailureEnrollment closed early in 2026 per sponsor decision.

JK07 (Salubris Biotherapeutics)

Phase 2 — Chronic Heart Failure

Sponsor: Salubris Biotherapeutics (JK07 Bio) · JK07.2.01 · NCT06369298

Enrollment closed early in 2026 per sponsor decision.

View study summary

Completed trials — selected

A selection of recent studies our team has executed across heart failure, ACS, hypertension, vascular, and cardiac imaging — covering sponsors from Boehringer Ingelheim, Novo Nordisk, GE Healthcare, AngioDynamics, Vifor, and more.

Phase 2Heart FailureCompleted2022–2024

CARDURION CRD-750-201 — Tovinontrine in HFrEF

Heart Failure with Reduced Ejection Fraction (HFrEF)

Cardurion CRD-750-201

Phase 2 study of tovinontrine, a PDE9 inhibitor, in HFrEF.

Sponsor: Cardurion Pharmaceuticals

Phase 2Heart FailureCompleted2022–2024

CARDURION CRD-750-202 — Tovinontrine in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Cardurion CRD-750-202

Phase 2 study of tovinontrine, a PDE9 inhibitor, in HFpEF.

Sponsor: Cardurion Pharmaceuticals

Phase 2Heart FailureCompleted2023–2024

R2R01 — Worsening Heart Failure

Worsening Heart Failure

R2R01-WHF-201

Sponsor: River 2 Renal

Phase 2Heart FailureCompleted(2024)

CARDINAL-HF (Cardurion — CRD-740)

Heart Failure

Cardurion CRD-740-201

Sponsor: Cardurion Pharmaceuticals

Heart FailureCompleted2022–2023

Cordio HearO — Voice Biomarker for HF

Heart Failure Decompensation Detection

Cordio CLN0011

Validation study of the Cordio HearO speech-based biomarker for early detection of heart failure decompensation.

Sponsor: Cordio Medical

Phase 3CardiologyCompleted2021–2023

GE Flurpiridaz F-18 — GE265-001

Myocardial Perfusion Imaging

GE Healthcare GE265-001

Sponsor: GE Healthcare

Phase 3CardiologyCompleted2022–2024

AURORA — Flurpiridaz F-18 — GE265-303

Myocardial Perfusion Imaging

GE Healthcare GE265-303

Sponsor: GE Healthcare

PivotalVascularCompleted2021–2023

Pathfinder I — AURYON EX-PAD-05

Peripheral Artery Disease

AngioDynamics EX-PAD-05

Pivotal Pathfinder I study of the AURYON Atherectomy + Thrombectomy system for peripheral artery disease.

Sponsor: AngioDynamics

Phase 3CardiologyCompleted2021–2022

ARISE — Bucillamine

Severe Cardiopulmonary Inflammation

Revive RT-003

Sponsor: Revive Therapeutics

Phase 3Heart FailureCompleted2020–2022

DIAMOND — Patiromer

Hyperkalemia in Heart Failure

Vifor PAT-CR-302

Phase 3 DIAMOND study of patiromer to enable RAASi therapy in HFrEF patients with hyperkalemia.

Sponsor: Vifor Pharma

Heart FailureCompleted2022–2023

ImpediMed Home Fluid Monitoring (HF)

Heart Failure Fluid-Status Monitoring

ImpediMed HF Study

Sponsor: ImpediMed

Phase 3Heart FailureCompleted2019–2021

EMPERIAL-preserved — Empagliflozin (HFpEF)

HFpEF — Exercise Capacity

Boehringer 1245-0167

Sponsor: Boehringer Ingelheim

Phase 3Heart FailureCompleted2019–2021

EMPERIAL-reduced — Empagliflozin (HFrEF)

HFrEF — Exercise Capacity

Boehringer 1245-0168

Sponsor: Boehringer Ingelheim

Sponsors: details on additional completed studies — including enrollment metrics, monitor reports, and audit history — are available on request under CDA. Request the full track record.